https://doi.org/10.1093/annonc/mdt494
M
Martin Filipits
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
379
Papers
12.9K
Citations
57
h-index
154
i10-index
Martin Filipits is an academic researcher from Comprehensive Cancer Center Vienna. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Breast Cancer Treatment Studies & Cancer Genomics and Diagnostics. The author has an h-index of 57, co-authored 323 publications.
ORCID: 0000-0003-2847-4534Papers by this author
worksPredicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
2013 · Annals of Oncology · 397 citations
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
2013 · British Journal of Cancer · 347 citations
https://doi.org/10.1038/bjc.2013.671
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
2012 · Annals of Oncology · 213 citations
https://doi.org/10.1093/annonc/mds334
Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group
2005 · Journal of Clinical Oncology · 103 citations
https://doi.org/10.1200/jco.2005.03.033
High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
2013 · British Journal of Cancer · 97 citations
https://doi.org/10.1038/bjc.2013.31
MRP and MDR1 gene expression in primary breast carcinomas.
1996 · PubMed · 94 citations
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat